Medicine and Dentistry
Patient
100%
Diagnosis
21%
Recurrent Disease
21%
Transurethral Resection
21%
Carcinoma in Situ
21%
Papilloma
21%
Association
21%
Urology
21%
Neoplasm
14%
Non Muscle Invasive Bladder Cancer
14%
Non Muscle Invasive Treatment of Bladder Cancer
14%
Lesion
7%
Surgery
7%
Tumor Progression
7%
Immunotherapy
7%
Tumor Recurrence
7%
Transitional Cell Carcinoma
7%
High Risk Population
7%
Intermediate Risk Population
7%
Cystectomy
7%
Evaluation Study
7%
Scoring System
7%
Cystoscopy
7%
Bladder Biopsy
7%
Bladder
7%
Tissues
7%
Muscle
7%
Nursing and Health Professions
Practice Guideline
28%
Recurrent Disease
21%
Transurethral Resection
21%
Chemotherapy
21%
Carcinoma in Situ
21%
Papilloma
21%
Diagnosis
21%
Neoplasm
14%
Non Muscle Invasive Bladder Cancer
14%
Prognosis
7%
Surgery
7%
Clinical Practice
7%
High Risk Population
7%
Cystoscopy
7%
Bladder Biopsy
7%
Adjuvant Therapy
7%
Transitional Cell Carcinoma
7%
Tumor Recurrence
7%
Cystectomy
7%
Tumor Growth
7%
Scoring System
7%
Immunotherapy
7%
Intermediate Risk Population
7%
Evaluation Study
7%
Synthesis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Recurrent Disease
21%
Bacillus
21%
Carcinoma in Situ
21%
Papilloma
21%
Neoplasm
14%
Non Muscle Invasive Bladder Cancer
14%
Prognosis
7%
Immunotherapy
7%
Transitional Cell Carcinoma
7%
Tumor Growth
7%
Tumor Recurrence
7%
Biochemistry, Genetics and Molecular Biology
Papillary Tumor
21%
Bacillus
21%
Association
21%
Synthesis
7%
Intermediate Risk Population
7%
High Risk Population
7%
Neuroscience
Chemotherapy
21%
Immunotherapy
7%